Claims for Patent: 10,716,799

Summary for Patent: 10,716,799

Title:	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Abstract:	The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.
Inventor(s):	Lind; Marianne (Bagsv.ae butted.rd, DK), Rasmussen; Gritt (Virum, DK), Sonne; Mette Rydahl (Brondby Strand, DK), Hansen; Jens (Virum, DK), Petersson; Karsten (Ballerup, DK)
Assignee:	LEO Pharma A/S (Ballerup, DK)
Application Number:	16/554,586
Patent Claims:	1. A sprayable, substantially anhydrous topical composition comprising calcipotriol or calcipotriol monohydrate, betamethasone dipropionate, a pharmaceutically acceptable propellant, present in amount between 45-95% w/w of the total composition, a pharmaceutically acceptable lipid carrier, present in an amount between 5-55% w/w of the total composition, and a pharmaceutically acceptable antioxidant, wherein the composition does not include propylene glycol, wherein visible crystals of the calcipotriol or calcipotriol monohydrate or the betamethasone dipropionate are not observed, as determined by polarized light microscopy, after storage of the composition for 12 months at about 25.degree. C. 2. The composition of claim 1, wherein each gram of the composition, excluding any mass contributed by any pharmaceutically acceptable propellant, comprises 52.2 mcg of calcipotriol monohydrate and 0.643 mg betamethasone dipropionate. 3. The composition of claim 2, wherein the composition further comprises a pharmaceutically acceptable lipophilic viscosity increasing ingredient. 4. The composition of claim 1, wherein the pharmaceutically acceptable propellant comprises a C.sub.3-5 alkane. 5. The composition of claim 4, wherein the C.sub.3-5 alkane is propane, isopropane, n-butane, isobutane, or mixtures thereof. 6. The composition of claim 5, wherein the C.sub.3-5 alkane is n-butane. 7. The composition of claim 2, wherein the pharmaceutically acceptable propellant comprises dimethyl ether. 8. The composition of claim 1, wherein the pharmaceutically acceptable lipid carrier comprises petrolatum. 9. The composition of claim 8, wherein the composition further comprises a pharmaceutically acceptable oily co-solvent. 10. The composition of claim 9, wherein the oily co-solvent comprises a compound of general formula I: H(OCH.sub.2C(CH.sub.3)H).sub.xOR.sup.1 wherein R.sup.1 is a straight or branched chain C.sub.1-20 alkyl, and x is an integer from 2 to 60 inclusive. 11. The composition of claim 10, wherein the compound of general formula I is polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether, or polyoxypropylene-3-myristyl ether. 12. The composition of claim 9, wherein the oily co-solvent comprises an isopropyl ester of a straight or branched chain C.sub.10-18 alkanoic or alkenoic acid. 13. The composition of claim 12, wherein the isopropyl ester of a straight or branched chain C.sub.10-18 alkanoic or alkenoic acid is isopropyl myristate, isopropyl palmitate, isopropyl isostearate, isopropyl linolate, or isopropyl monooleate. 14. The composition of claim 9, wherein the oily co-solvent comprises a straight or branched C.sub.8-24 alkanol or alkenol. 15. The composition of claim 14, wherein (i) the straight C.sub.8-24 alkanol is capryl alcohol, lauryl alcohol, cetyl alcohol, stearyl alcohol, or myristyl alcohol, (ii) the straight C.sub.8-24 alkenol is oleyl alcohol or linoleyl alcohol, and/or (iii) the branched C.sub.8-24 alkanol is a branched C.sub.18-24 alkanol. 16. The composition of claim 15, wherein the straight C.sub.8-24 alkanol is myristyl alcohol. 17. The composition of claim 9, wherein the calcipotriol or calcipotriol monohydrate is present in an amount between 0.001-0.05% w/w of the total composition, the betamethasone dipropionate is present in an amount between 0.0005-1% w/w of the total composition, and the pharmaceutically acceptable oily co-solvent is present in an amount between 0.1-10% w/w of the total composition. 18. The composition of claim 17, wherein the composition comprises calcipotriol, wherein the calcipotriol is present in an amount of 0.005% w/w of the composition, excluding any mass contributed by any pharmaceutically acceptable propellant, and the betamethasone dipropionate is present in an amount of 0.064% w/w of the composition, excluding any mass contributed by any pharmaceutically acceptable propellant. 19. The composition of claim 17, wherein the composition comprises calcipotriol monohydrate, wherein the calcipotriol monohydrate is present in an amount of 0.00522% w/w of the composition, excluding any mass contributed by any pharmaceutically acceptable propellant, and the betamethasone dipropionate is present in an amount of 0.064% w/w of the composition, excluding any mass contributed by any pharmaceutically acceptable propellant. 20. The composition of claim 19 wherein the pharmaceutically acceptable oily co-solvent is myristyl alcohol. 21. The composition of claim 2, wherein the pharmaceutically acceptable propellant comprises dimethyl ether; the pharmaceutically acceptable lipid carrier is a mixture of liquid paraffin and petrolatum. 22. The composition of claim 21, further comprising a pharmaceutically acceptable oily co-solvent. 23. The composition of claim 1, wherein visible crystals of the calcipotriol or calcipotriol monohydrate or the betamethasone dipropionate have not formed after storage of the composition for 18 months at about 25.degree. C. 24. The composition of claim 1, wherein visible crystals of the calcipotriol or calcipotriol monohydrate or the betamethasone dipropionate have not formed after storage of the composition for 24 months at about 25.degree. C. 25. The method of treatment of claim 8, wherein the petrolatum is white soft paraffin. 26. The method of treatment of claim 21, wherein the petrolatum is white soft paraffin.